Piper Sandler Reaffirms Their Buy Rating on Solventum Corporation (SOLV)
In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Solventum Corporation, with a price target of $92.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Bednar is an analyst with an average return of -5.4% and a 38.90% success rate. Bednar covers the Healthcare sector, focusing on stocks such as NovoCure, Merit Medical Systems, and Align Tech.
In addition to Piper Sandler, Solventum Corporation also received a Buy from BTIG’s Ryan Zimmerman in a report issued on April 13. However, on April 8, Bank of America Securities maintained a Hold rating on Solventum Corporation (NYSE: SOLV).
Based on Solventum Corporation’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2 billion and a net profit of $63 million. In comparison, last year the company earned a revenue of $2.08 billion and had a net profit of $31 million
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SOLV in relation to earlier this year. Last month, Amy Mcbride Wendell, a Director at SOLV bought 1,475.00 shares for a total of $100,344.25.
Read More on SOLV:
